The information presented on this website, including but not limited to any forward-looking statements, forecasts, or business projections, is for informational purposes only and are based upon various assumptions, and these assumptions may prove to be incorrect. These forward-looking statements, forecasts, and business projections are based on current expectations and assumptions which may change over time due to various market factors, economic conditions, and business decisions. Actual results may differ materially from those expressed or implied in any projections or forecasts. They should not be construed as financial or investment advice. We make no guarantees regarding the performance or outcomes described and do not assume nor accept any responsibility for the accuracy or completeness of these statements and we do not accept liability for any loss or damages that may arise from reliance on this information. You are encouraged to perform your own due diligence and consult with a qualified financial advisor before making any business or investment decisions.
*The testimonials provided through this website are given by investors who have invested cash into Endless Corporation in exchange for securities of the company, and they are offering such testimonials in their individual capacity. Such persons have not received and will not receive in the future compensation for providing such testimonials.
Reg A
**In no way limiting the foregoing, any reference to any objective, goal, intention, or plan of Endless Corporation becoming, emulating, or operating in a similar manner as Fortune 100 and 500 companies is not a guarantee that it will be able to do so, or will not elect to do otherwise, now or in the future. In addition, while this website may reference aspirations of Endless Corporation for a future public listing, it is still formulating and has not yet decided on or yet implemented a plan to achieve such result. Future results are not guaranteed, nor is how, the capability to achieve such results, and no investment decision should be based upon the potential of a future public listing, or any other potential future event discussed herein.
These offering materials may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. These forward-looking statements are based on the beliefs of, assumptions made by, and information currently available to the company's management. When used in the offering materials, the words "estimate," "project," "believe," "anticipate," "intend," "expect" and similar expressions are intended to identify forward-looking statements. These statements reflect management's current views with respect to future events and are subject to risks and uncertainties that could cause the company's actual results to differ materially from those contained in the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made. The company does not undertake any obligation to revise or update these forward-looking statements to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.
Please note investors in this offering will be clients of the issuer and not Dalmore Group, LLC ("Dalmore"), a registered broker-dealer and member FINRA/SIPC. Dalmore's role in the transaction is to facilitate back-office and regulatory functions related to the Regulation A transaction, and acts only as the broker/dealer of record for the offering listed. Dalmore is not providing investment advice or recommendations, or legal or tax advice.
This Reg A investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. All investors should make their own determination, with the assistance of their own financial or other advisors, as to whether or not to make any investment, based on their own independent evaluation, analysis, and circumstances.
No money or other consideration is being solicited, and if sent in response, will not be accepted. No offer to buy the securities can be accepted and no part of the purchase price can be received until the offering statement filed by the company with the SEC has been qualified by the SEC. Any such offer may be withdrawn or revoked, without obligation or commitment of any kind, at any time before notice of acceptance given after the date of qualification. An indication of interest involves no obligation or commitment of any kind. An offering statement regarding this offering has been filed with the SEC. You may obtain a copy of the preliminary offering circular that is part of that offering statement. Form 1-A Filing with SEC
Last updated: April 23, 2026
Effective April 12, 2026. Last updated April 23, 2026.
This Privacy Notice explains how Endless Corporation, Inc. collects, uses, shares, and protects personal information. It applies to visitors of our website, prospective and current investors, commercial clients, and anyone who corresponds with us. It is written to meet the requirements of the EU General Data Protection Regulation (EU GDPR), the UK General Data Protection Regulation (UK GDPR), and applicable U.S. state privacy laws. If any provision conflicts with mandatory local law, the local law controls for residents of that jurisdiction.
The controller of your personal information is Endless Corporation, Inc., a Delaware corporation with its principal place of business at 10026A South Mingo Rd #232, Tulsa, Oklahoma 74133, United States. You can reach us by email at privacy@endlessbiotech.com or by phone at (918) 786 0200. For the purposes of the EU GDPR (Article 27) and the UK GDPR, we are in the process of appointing an EU representative and a UK representative. Until appointment is complete, you may address GDPR inquiries to privacy@endlessbiotech.com and we will route them accordingly.
We collect only the information we need for the purposes described below. Depending on how you interact with us, the categories of personal information we collect may include:
Most information comes directly from you when you fill out a form, correspond with us, or subscribe to an offering. For investors we also receive information from our broker-dealer Dalmore Group, LLC, from identity verification and sanctions-screening providers, from credit reference agencies where permitted, and from public sources such as sanctions lists and corporate registries. If we receive your information from a third party, we will tell you the source when we first communicate with you, as required by Article 14 of the GDPR.
We only process personal information where we have a lawful basis to do so. Our purposes and the corresponding legal bases are:
We do not sell personal information. We share it only with the following categories of recipients, and only as necessary for the purposes listed above:
We are established in the United States and most of our service providers are based in the United States. When personal information of individuals in the European Economic Area or the United Kingdom is transferred outside those regions, we rely on one or more transfer mechanisms recognised by GDPR: the EU-U.S. Data Privacy Framework (and the UK Extension) where the recipient is certified; the European Commission's Standard Contractual Clauses and the UK International Data Transfer Addendum; or a derogation in Article 49 where no other mechanism is available and the transfer is necessary. A list of our current processors and their transfer mechanisms is available on request by writing to privacy@endlessbiotech.com.
We keep personal information only as long as necessary for the purposes for which it was collected, or as required by law. Our main retention periods are:
If the EU GDPR or the UK GDPR applies to the processing of your personal information, you have the rights listed below. You can exercise any of them by writing to privacy@endlessbiotech.com. We will respond within one month, which we may extend by a further two months where a request is complex, in which case we will tell you within the first month.
Write to privacy@endlessbiotech.com with enough detail for us to locate your information and verify your identity. We will ask for two pieces of information that match what we already hold (such as the email you used to contact us and a subscription reference, if applicable) rather than copies of identity documents, to avoid creating additional risk. Exercising these rights is free unless your request is manifestly unfounded or excessive, in which case we may charge a reasonable fee or decline to act. We will tell you before we do either.
Our website uses strictly necessary cookies for the site to function. After you give consent through our cookie banner, we also deploy the following non-essential trackers: Meta Pixel (Facebook Pixel ID 26737078329246778) for conversion measurement and remarketing; Google Analytics 4 (measurement ID G-WB556C2BD5) for aggregate traffic and user-journey analytics; and, where active, Google Ads conversion tags. All three fire only after explicit consent, track across soft-navigation route changes, and stop immediately if you withdraw consent. You can refuse or withdraw consent at any time without detriment to your use of the site; refusing these trackers does not affect your access to any content. A current list of cookies and trackers in use is available in our Cookie Notice.
When we send you a marketing email, such as investor updates or syndicate communications you have subscribed to, the message contains two tracking mechanisms:
We apply technical and organisational measures appropriate to the risk of processing, including encryption of data in transit using TLS 1.3 and encryption at rest using AES-256 where supported by our providers, role-based access control, audit logging, vendor due diligence, and incident response procedures. No system is perfectly secure and we cannot guarantee absolute security, but we review and improve our controls regularly.
We do not make decisions about you that are based solely on automated processing and that produce legal effects concerning you or similarly significantly affect you. Where we use automated tools to screen for sanctions, fraud, or anti-money-laundering red flags, a human reviewer makes the final decision on any outcome that affects your ability to invest or transact with us.
Our website and offerings are not directed to children under 18, and we do not knowingly collect personal information from them. If you believe a child has provided us with information, contact privacy@endlessbiotech.com and we will delete it.
We may update this notice to reflect changes in our processing, our service providers, or applicable law. The date at the top of this page shows when it was last updated. Material changes will be signalled on the website or communicated to you directly where we have your contact details.
You have the right to complain to a data protection supervisory authority. In the United Kingdom, the Information Commissioner's Office (ico.org.uk, 0303 123 1113). In Ireland, the Data Protection Commission (dataprotection.ie). In other EU member states, the national data protection authority of the country where you live or work, or where the alleged infringement occurred. A directory is maintained by the European Data Protection Board at edpb.europa.eu. We would appreciate the chance to address your concerns before you contact a regulator, so please consider writing to privacy@endlessbiotech.com first.
For any question about this notice or our processing of your personal information, contact us at privacy@endlessbiotech.com, by phone at (918) 786 0200, or by post at Endless Corporation, Inc., Attn: Privacy, 10026A South Mingo Rd #232, Tulsa, Oklahoma 74133, USA.